NCT07640685
UCLA Magnesium Formulation Athlete Study
Not Yet Recruiting
NAAges 18–35InterventionalUniversity of California, Los AngelesInvestigator-initiated
~150 participants
Updated 2026-06-11 on ClinicalTrials.gov
What's tested:Magnesium glycinateMagnesium L-threonatePlacebo
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in WHOOP-derived sleep efficiency percentage from baseline week to final treatment week
Measured over Baseline week to final treatment week, approximately 5 weeks total including baseline monitoring
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Jeremy Swisher, MD · PRINCIPAL_INVESTIGATOR · University of California, Los Angeles
- Joshua Goldman, MD · STUDY_DIRECTOR · University of California, Los Angeles
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age 18 to 35 years.
Current UCLA varsity athlete.
Actively training or competing during the study period.
Willing to wear WHOOP or a study-approved wearable device continuously during baseline and treatment periods if wearable data are used.
Willing to take assigned study capsules nightly for 28 days.
Willing to complete brief daily REDCap surveys and weekly adherence/safety check-ins.
Able to provide informed consent and comply with study procedures.
Exclusion
Current magnesium supplementation without completion of an appropriate washout before baseline.
Current investigational drug or investigational supplement use.
Current use of prescription or over-the-counter sleep medications unless reviewed and permitted by the study clinician.
Diagnosed sleep disorder that, in the investigator's judgment, would confound outcomes or increase risk.
Significant kidney disease or another medical condition that may increase risk with magnesium supplementation.
Known intolerance or allergy to magnesium glycinate, magnesium L-threonate, placebo, or inactive study ingredients.
Use of medications with clinically relevant magnesium interactions unless reviewed and permitted by the study clinician.
Any other condition that, in the investigator's judgment, would make participation unsafe, compromise voluntary consent, or prevent valid outcome assessment.
What this trial measures
- Change in WHOOP-derived sleep efficiency percentage from baseline week to final treatment weekBaseline week to final treatment week, approximately 5 weeks total including baseline monitoring
Average nightly WHOOP-derived sleep efficiency, expressed as a percentage, will be calculated for the baseline week and final treatment week. A valid week requires at least 5 usable nights in the 7-day window. The outcome is final-treatment-week average minus baseline-week average; higher values indicate improved sleep efficiency.